1bx8: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1bx8.jpg|left|200px]]
{{Seed}}
[[Image:1bx8.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1bx8|  PDB=1bx8  |  SCENE=  }}  
{{STRUCTURE_1bx8|  PDB=1bx8  |  SCENE=  }}  


'''HIRUSTASIN FROM HIRUDO MEDICINALIS AT 1.4 ANGSTROMS'''
===HIRUSTASIN FROM HIRUDO MEDICINALIS AT 1.4 ANGSTROMS===




==Overview==
<!--
BACKGROUND: Leech-derived inhibitors have a prominent role in the development of new antithrombotic drugs, because some of them are able to block the blood coagulation cascade. Hirustasin, a serine protease inhibitor from the leech Hirudo medicinalis, binds specifically to tissue kallikrein and possesses structural similarity with antistasin, a potent factor Xa inhibitor from Haementeria officinalis. Although the 2.4 A structure of the hirustasin-kallikrein complex is known, classical methods such as molecular replacement were not successful in solving the structure of free hirustasin. RESULTS: Ab initio real/reciprocal space iteration has been used to solve the structure of free hirustasin using either 1.4 A room temperature data or 1.2 A low temperature diffraction data. The structure was also solved independently from a single pseudo-symmetric gold derivative using maximum likelihood methods. A comparison of the free and complexed structures reveals that binding to kallikrein causes a hinge-bending motion between the two hirustasin subdomains. This movement is accompanied by the isomerisation of a cis proline to the trans conformation and a movement of the P3, P4 and P5 residues so that they can interact with the cognate protease. CONCLUSIONS: The inhibitors from this protein family are fairly flexible despite being highly cross-linked by disulphide bridges. This intrinsic flexibility is necessary to adopt a conformation that is recognised by the protease and to achieve an optimal fit, such observations illustrate the pitfalls of designing inhibitors based on static lock-and-key models. This work illustrates the potential of new methods of structure solution that require less or even no prior phase information.
The line below this paragraph, {{ABSTRACT_PUBMED_10368273}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 10368273 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_10368273}}


==About this Structure==
==About this Structure==
Line 34: Line 38:
[[Category: Peptidic inhibitor]]
[[Category: Peptidic inhibitor]]
[[Category: Serine protease inhibitor]]
[[Category: Serine protease inhibitor]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May  2 12:04:19 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jun 30 19:51:41 2008''